 Biotransformation
"Biotransformation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
| Descriptor ID |
D001711
|
| MeSH Number(s) |
G03.495.244 G03.787.225 G07.690.725.225
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Biotransformation".
Below are MeSH descriptors whose meaning is more specific than "Biotransformation".
This graph shows the total number of publications written about "Biotransformation" by people in this website by year, and whether "Biotransformation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 3 | 3 | | 1998 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2012 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2015 | 0 | 7 | 7 | | 2016 | 0 | 4 | 4 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Biotransformation" by people in Profiles.
-
Stancil SL, Nolte W, Pearce RE, Staggs VS, Leeder JS. The Impact of Age and Genetics on Naltrexone Biotransformation. Drug Metab Dispos. 2022 02; 50(2):168-173.
-
Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
-
Gaedigk A. Pharmacogenetics: Chasing Perfection. Clin Pharmacol Ther. 2019 08; 106(2):265-270.
-
Yang JJ, Whirl-Carrillo M, Scott SA, Turner AJ, Schwab M, Tanaka Y, Suarez-Kurtz G, Schaeffeler E, Klein TE, Miller NA, Gaedigk A. Pharmacogene Variation Consortium Gene Introduction: NUDT15. Clin Pharmacol Ther. 2019 05; 105(5):1091-1094.
-
Goldman JL, Koen YM, Rogers SA, Li K, Leeder JS, Hanzlik RP. Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes. Drug Metab Dispos. 2016 10; 44(10):1603-7.
-
Leeder JS, Meibohm B. Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. Drug Metab Dispos. 2016 07; 44(7):916-23.
-
Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children. Drug Metab Dispos. 2016 07; 44(7):1070-9.
-
Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther. 2016 06; 99(6):642-50.
-
Pearce RE, Gaedigk R, Twist GP, Dai H, Riffel AK, Leeder JS, Gaedigk A. Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation. Drug Metab Dispos. 2016 07; 44(7):948-58.
-
Dodgen TM, Labuschagne CJ, van Schalkwyk A, Steffens FE, Gaedigk A, Cromarty AD, Alessandrini M, Pepper MS. Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics J. 2016 11; 16(6):566-572.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|